Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies-Reference-Cited by-同舟云学术

Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies

Published:2023-03-09 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Sun Chenxi¹^ORCID,Chen Huixian²^ORCID,Wang Yongjing³⁴⁵,Zheng Chengyun³⁴⁵^ORCID

Affiliation:

1. The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China

2. Center for Clinical Research, The Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of China

3. Department of Hematology, The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China

4. Institute of Biotherapy for Hematological Malignancies, Shandong University, Jinan, Shandong, People’s Republic of China

5. Shandong University-Karolinska Institute Collaboration Laboratory for Stem Cell Research, Jinan, Shandong, People’s Republic of China

Funder

the Key Research and Development Program of Shandong Province

Shandong University

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2181749

Reference55 articles.

1. Epidemiology Of Hodgkin's disease: a review

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

3. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

4. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

5. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study;Annals of Hepatology;2024-09

2. Living in LALA land? Forty years of attenuating Fc effector functions;Immunological Reviews;2024-08-19

3. Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma;Cancers;2024-02-28

4. Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2024-01

5. Suspected NUT Carcinoma Progressing on Pembrolizumab, Carboplatin, and Paclitaxel as First-Line Treatment: A Case Report;Annals of Medicine & Surgery;2023-12-04